Throughout this application various publications are referenced, most typically by the last name of the first author and the year of publication. Full citations for these publications are set forth in a section entitled References immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which the invention relates.
Every function of neurons, including sensation, action, cognition, learning, and memory, involves highly coordinated interactions among large networks of proteins. Proteomic studies of both pre-synaptic and post-synaptic compartments have enumerated hundreds of different proteins that are organized into clustered interaction networks (Abul-Husn 2009, Li 2004, Choudhary 2006, Yoshimura 2004, Collins 2006, Husi 2000, Pocklington 2006). With the emergence of systems biology and proteomics, it has become increasingly clear that developing robust, predictive models of the molecular mechanisms of cellular functions such as learning and memory will require an understanding of how these networks of molecular interactions function. Molecular interaction networks are becoming increasingly central to drug design. Systems level phenomena such as cross talk between signaling pathways and ‘off-target’ drug interactions lead to adverse side effects and poor drug efficacy, together accounting for 30% of all drug failures in clinical trials (Hopkins, 2008). From the perspective of both basic and translational neuroscience, the systems level analysis of molecular interaction networks is an emerging paradigm that promises to be transformative.
Experimental approaches to detecting large sets of molecular interactions in cells have been limited. Biochemical methods for detecting protein-protein interactions, such as co-immunoprecipitation, are able to detect large numbers of interactions, enabling the reconstruction of complex interaction networks. However, these approaches typically involve homogenizing a large volume of the cell/tissue sample, thereby losing a great deal of information about the spatial variation of protein interaction networks. This spatial variation is particularly important in highly heterogeneous tissues such as the brain, where interaction networks are expected to vary not only from cell type to cell type (e.g neurons versus glia) but also from compartment to compartment within the same cell (e.g. dendritic spine versus dendritic shaft).
The ability to stain a single fixed cell or tissue sample with many different fluorescent probes for many different biomolecules i) maximizes the information that can be gained from a single cell/tissue sample and ii) reveals relationships between the spatial distributions of these biomolecules that might not have been evident had they been probed individually on many different samples. Because of the advantages of single sample staining, several approaches have been developed to stain a sample with multiple probes either simultaneously or sequentially. These approaches are typically (though not always) collectively called ‘multiplex imaging’ (Gerdes et al., 2013; Jungmann et al., 2014; Micheva & Smith, 2007; Nelson et al., 2013; Schubert et al., 2006). Multiplex imaging holds tremendous potential to elucidate how large sets of proteins are spatially coordinated and therefore how molecular interaction networks vary spatially.
The present invention provides several advantages over existing multiplex imaging approaches.
The subject invention provides a selectively cleavable probe comprising an F(ab) fragment linked to one or more labels by a chemically cleavable disulfide bond.
The subject invention also provides a process of immunostaining a sample comprising staining the sample with a selectively cleavable probe.
The subject invention further provides a process of immunostaining a sample comprising
(B) Cleavable bond N═N. Excitation induced non-cleavability was not unique to disulfide linkage of the fluorophore, nor did it require a direct covalent path from the cleavable bond to the fluorophore. In the Myosin 2B staining depicted, the F(ab) fragment was conjugated to biotin via a cleavable diazo bond. The biotin was then detected using an Alexa 488 labeled Streptavidin or anti-biotin IgG. Despite the significantly different molecular structures involved, photo-excitation still yielded a non-cleavable residual stain.
The subject invention provides a selectively cleavable probe comprising an F(ab) fragment linked to one or more labels by a chemically cleavable disulfide bond.
In one embodiment, the label is a fluorescent label. In another embodiment, the label is a fluorescent protein.
In an alternative embodiment, the F(ab) fragment is a monovalent F(ab) fragment from a secondary IgG antibody. In another embodiment, the F(ab) fragment is an anti-Rabbit fragment. In a further embodiment, the F(ab) fragment is an anti-Mouse F(ab) fragment. In another embodiment, the F(ab) fragment is an anti-Rabbit F(ab) fragment, anti-Mouse F(ab) fragment or another species specific F(ab) fragment.
In one embodiment, the F(ab) fragment is an anti-biotin F(ab) fragment.
In alternative embodiments, the fluorescent protein is selected from the group consisting of a Green Fluorescent Protein (GFP), Yellow Fluorescent Protein (YFP), Cyan Fluorescent Protein (CFP), and mCherry. In another embodiment, the fluorescent protein is a green fluorescent protein (GFP) or a similar protein. In a further embodiment, the fluorescent protein is a Green Fluorescent Protein (GFP). In an additional embodiment, the fluorescent protein is a fluorescent phycobiliprotein. In another embodiment, the fluorescent phycobiliprotein is allophycocyanin, phycocyanin, phycoerythrin, or phycoerythrocyanin.
In alternative embodiments, the fluorescent protein comprises a small fluorescent group surrounded by an inert shell that prevents the fluorophore from coming in contact with its surroundings. In another embodiment, the fluorescent protein comprises a small fluorescent group surrounded by proteins. In a further embodiment, the fluorescent protein comprises a small fluorescent group surrounded by a protein beta barrel. In further embodiments, the fluorescent label does not form a non-cleavable bond with its surroundings upon excitation with light.
In alternative embodiments, the label comprises a fluorophore surrounded by an inert shell that prevents the fluorophore from coming in contact with its surroundings. In another embodiment, the label comprises a fluorophore surrounded by proteins. In a further embodiment, the label comprises a fluorophore surrounded by a protein beta barrel. In further embodiments, the fluorophore does not form a non-cleavable bond with its surroundings upon excitation with light. In an embodiment, the fluorophore is a fluorescent group.
In another embodiment, the label is not a small-molecule fluorophore. In some embodiments, the label is a small-molecule fluorophore
The subject invention also provides a process of immunostaining a sample comprising staining the sample with a selectively cleavable probe.
The subject invention further provides a process of immunostaining a sample comprising
In an embodiment, the primary antibody against the preselected target is conjugated to biotin or linked to biotin by a disulfide bond. In another embodiment, the primary antibody against the preselected target is linked to biotin by a disulfide bond.
In alternative embodiments, the process further comprises washing off any unbound primary antibody after step b).
In one embodiment, the process further comprises imaging the sample after staining the sample with the selectively cleavable probe.
In another embodiment, the process further comprises destaining the sample by cleaving the bond between the F(ab) fragment and the one or more fluorescent proteins.
In one embodiment the destaining comprises contacting the sample with a reducing agent. In an embodiment, the amount of the reducing agent is 5-50 mM or 20-50 mM. In another embodiment, the reducing agent is a disulfide reducing agent. In a further embodiment, the reducing agent is tris(2-carboxyethyl)phosphine (TCEP) or Dithiothreitol (DTT).
In another embodiment, the destaining is performed under near physiological conditions or under mild conditions.
In alternative embodiments, the process further comprises cleaving unbound biotin moieties on the primary antibody.
In one embodiment, the process further comprises the step of staining the sample with a permanent label that is unaffected by disulfide reducing agents. In an embodiment, the permanent label is phalloidin-Alexa 647.
In one embodiment, the permanent stain is not affected by the destaining.
In an embodiment, the target is selected from the group consisting of a protein, and an antigen.
In alternative embodiments, the process further comprises repeating the process for a second preselected target.
In alternative embodiments, the process further comprises repeating the process for a third preselected target. In another embodiment, the process further comprises repeating the process for a fourth preselected target. In a further embodiment, the process further comprises repeating the process for a fifth preselected target. In another embodiment, the process further comprises repeating the process 6 or more times for additional preselected targets.
In another embodiment, the sample is not degraded during the process.
The invention further provides a selectively cleavable probe comprising an F(ab) fragment linked to one or more fluorescent proteins by a chemically cleavable disulfide bond to form a F(ab)-SS-GFP probe. See
In an embodiment, the label is a dye. In another embodiment, the label is a small molecule fluorophore. In a further embodiment, the small molecule fluorophore is fluorescein, or Cy5. The small molecule fluorophore may be any known small molecule fluorophore. In another embodiment, the F(ab) fragment is from a secondary IgG antibody. In an additional embodiment, the F(ab) fragment is a monovalent F(ab) fragment.
Any known disulfide reducing agent may be used in this the process of this invention. Many of disulfide reducing agents are commercially available. Common disulfide reducing agents include Tris(2-carboxyethyl) phosphine (TCEP), and Dithiothreitol (DTT).
Fluorescent phycobiliproteins may be used as labels. This family consists of a small fluorescent group surrounded by a large protein. Structurally, they are similar to GFP (or YFP, CFP, mCherry, etc) in that they have a small fluorescent group surrounded by proteins. Because fluorescent phycobiliproteins have this basic structural commonality where the fluorescent group is embedded inside the protein, excitation of the fluorescent group does not lead to formation of a bond with the intracellular environment.
Where a range is given in the specification it is understood that the range includes all integers and 0.1 units within that range, and any sub-range thereof. For example, a range of 77 to 90% includes 77.0%, 77.1%, 77.2%, 77.3%, 77.4%, 77.5%, 77.6%, 77.7%, 77.8%, 77.9%, 80.0%, 80.1%, 80.2%, 80.3%, 80.4%, 80.5%, 80.6%, 80.7%, 80.8%, 80.9%, and 90.0%, as well as the range 80% to 81.5% etc.
All combinations of the various elements described herein are within the scope of the invention.
This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
In sequential or iterative multiplex imaging, the typical strategy is to i) apply a single fluorescent probe to a sample, ii) image its distribution in a specific region of the sample with a fluorescence microscope, and iii) permanently deactivate the fluorescence of that probe optically or chemically (known as destaining or deactivation). This staining, imaging, destaining protocol is repeated for many different probes and ultimately generates a composite image of the distribution of many different stains.
The current generation of techniques and probes for iterative staining have several limitations:
i) Moderate to no fluorescence destaining specificity. It is often desirable to stain a sample with two types of probes—the deactivatable probes mentioned above that iteratively stain many different molecules, and one or more permanent stain(s) that will persist throughout the iterative staining process e.g. to label a specific cell type or organelle. Current approaches for iterative staining do not permit the selective and complete destaining of the iterative probe without affecting the permanent probe.
ii) The iterative stain cannot be completely deactivated under mild conditions. Typically, in order to completely destain the sample, severe buffer conditions are required (low pH, high osmolarity, etc.) (Micheva & Smith, 2007) that can damage the sample itself. Moreover, as shown below, the very act of imaging a fluorophore creates a reactive excited state of that fluorophore that can cause it to covalently bind to other nearby intracellular molecules (Holden & Cremer, 2003). This covalent binding of the fluorophore to its surroundings makes it very difficult to chemically remove. Hence, the very act of imaging a destainable fluorophore can make it non-destainable.
To overcome these limitations, we have developed an iterative staining approach, and a class of fluorescent probes that can be completely and selectively deactivated on a sample under mild buffer conditions. These probes can be used for sequential multiplex imaging and offer the advantage that the sample is not exposed to harsh treatments, and other conventional, permanent stains on the sample will not be affected.
The gold standard for imaging protein-protein interactions in cells is Förster Resonance Energy Transfer (FRET), which is sensitive to distances of up to ˜100 Å between putatively interacting molecules. Because FRET requires two interacting molecules to be labeled with two different colors, the number of distinct binary interactions that can be imaged simultaneously on the same sample is limited by the number of colors that can be spectrally separately resolved within the wavelength range detectable by conventional fluorescence detectors. Currently, only a maximum of two separate FRET pairs have been convincingly, simultaneously imaged on the same sample (Grant 2008). Simultaneous imaging of a larger number of putative interactions would require a correspondingly larger palate of label colors.
A superior alternative to simultaneous labeling is sequential labeling in which a single sample is iteratively stained, imaged and then de-stained. It is relatively straightforward to image the same field of view in the sample and spatially co-align the images acquired from each imaging round during post-processing. Using this sequential staining approach, many stains (>10) can be imaged on a given sample, yielding a final composite spatial map of a large number of different proteins. In these techniques, de-staining is accomplished either by antibody elution buffers (Micheva 2010, Wahlby 2002) which strip the antibody probes from the sample or chemical deactivation of the fluorophore (Gerdes 2013) which destroys the fluorescent label on the antibody probe.
To measure several interactions with a given target protein, it is necessary to be able to sequentially stain and de-stain the interactors, without affecting the label on the target. The existing approaches for sequential staining therefore cannot be used to measure multiple binary interactions as their de-staining methods non-selectively destroy all stains on the sample. Elution buffers use low pH or high salt concentrations to partially denature proteins in the sample and thereby undo antibody-antigen binding. These harsh, denaturing conditions will also de-stain the target, and over repeated rounds will physically degrade the sample. Chemical deactivation of fluorophores is generally milder. In fact Gerdes et al (Gerdes 2013) have demonstrated that it is possible to sequentially stain a sample for 61 antigens. However, as before, while different fluorescent probes are differently susceptible to different chemical deactivation buffers, it is rare to find robust FRET pairs in which one fluorescent label can be entirely deactivated by a buffer while the other is unaffected by the same buffer.
The currently available methods discussed above cannot image more than two protein-protein interactions on the same sample using FRET. Simultaneous staining approaches lack an adequate spectral range, and sequential staining approaches lack sufficiently selective de-staining buffers. The sequential target interaction imaging method that we have begun to develop overcomes several of these limitations. The approach in the following Examples allows the interactors to be selectively de-stained with high specificity, causing no damage to either the target stain or any other ancillary stains on the sample (e.g. synaptic markers or whole cell labels). Moreover, a wide range of fluorophores can be used, allowing FRET pairs to be chosen at whatever wavelength is most convenient for the user. The techniques in the follow examples enables, for the first time, the imaging of many protein-protein interactions on the same region of interest and will thereby enable the reconstruction of the interactomes of key proteins important for neuronal function and identity.
Immunostains are conventionally done as, first, a stain with a primary antibody against a particular antigen, followed by another stain with a fluorescent secondary antibody against the host species of the primary antibody. An alternative to this staining protocol, that presents key advantages, involves using fluorescently labeled monovalent Fab fragments instead of conventional IgG secondary antibodies (Brown 2004). Monovalent Fab fragments are the ˜50 kD fragments of IgG antibodies that contain a single antigen binding site per fragment. They are obtained by digesting IgG antibodies with papain to sever the two Fab fragments from the Fc fragment Staining a specific antigen using Fab fragments (
The procedure of this example follows this general staining protocol, except we use monovalent Fab fragments that have been labeled with Fluorescein via a cleavable disulfide bond using standard disulfide labeling chemistry. Monovalent Fab fragments naturally contain a single disulfide bridge between proximate cysteine residues that is accessible under non-denaturing conditions (Liu 2012). Disulfide reducing agents such as TCEP or DTT reduce this superficial disulfide bond (-S-S-) to thiols (-SH), which are then reacted with fluorescein methanethiosulfonate to produce Fab fragments labeled with Fluorescein via disulfide bonds (Fab-SS-Fluorescein). While Fab-SS-Fluorescein is a stable conjugate under normal conditions, Fluorescein can be cleaved from the Fab fragment using the same disulfide reducing agents (TCEP or DTT) used to cleave the original disulfide bridge on the Fab fragment.
As an illustration,
The crucial advantage of using a Fab based staining protocol over a traditional primary+secondary antibody staining protocol now becomes clear. The complex of the primary antibody and fluorescent Fab is ultra-filtered to remove any unbound Fab prior to applying the complex to the sample. Hence there is no free fluorescent Fab in the staining solution applied to the sample that might stain primary antibodies deposited during previous staining rounds. This strategy ensures that only a single interactor is stained on any given round, even if the primary antibodies used in previous staining rounds derived from the same host species.
The covalent modification of a Fab fragment potentially alters its affinity for its antigen. Since only one superficial disulfide bridge per Fab fragment is modified, its structure and function are not likely to be affected. To confirm the functionality of Fab-SS-Fluorescein conjugates, COS-7 cells were stained with anti-Myosin 2b (
Fab-SS-Fluorescein stained samples can be de-stained using the disulfide reducing agent TCEP. A stain against Myosin 2b in COS-7 cells using Fab-SS-Fluorescein (
To demonstrate a set of sequential interaction measurements in which interactors are iteratively stained and de-stained while the target is unaffected, f-Actin was chosen as the target, since it is one of the most promiscuous interactors in the cell and has a demonstrable role in numerous forms of neuronal plasticity (Ramachandran 2009, Fischer 1998, Fischer 2000, Okamoto 2004, Lin 2010). F-Actin was first stained with the small molecule Phalloidin-Alexa 647. The first candidate interactor was then chosen, in this case Cam Kinase 2 (β/γ/δ pan antibody) (
During the initial development of this method, the interaction between f-Actin and any given interactor in a region of interest was defined as the co-localization (Pearson's correlation coefficient) of the two fluorescence signals in that region of interest. While co-localization is a poor measure of protein-protein interaction, we use it as a preliminary, qualitative indicator of interaction and plan to modify our method to use FRET to quantitatively measure interactions.
While co-localization of two fluorophores in a confocal microscope image is necessary for interaction, it is not generally a good measure of interactions because the spatial resolution of a confocal fluorescence microscope (˜200 nm) is much greater than the typical distance between interacting proteins (<100 Å). Two fluorophores may appear to co-localize even though they may be up to ˜200 nm apart, giving a false positive indication of interaction. We therefore plan to use Förster Resonance Energy Transfer (FRET), sensitive to distances less than 100 Å, to measure protein-protein interactions.
f-Actin was stained with a FRET acceptor label (Phalloidin-CF568) and α-N-Catenin with a primary antibody+Fab-SS-Fluorescein complex that serves as the FRET donor to demonstrate the feasibility of using FRET to detect the interaction of a target with a Fab-SS-Fluorescein stained interactor (
Using FLIM, it will also be possible to estimate the population fraction of the interactor (donor) that is bound to the target (acceptor) at every pixel. While the use of FLIM to quantitatively study protein-protein interaction is well established, combining sequential Fab staining with the FLIM imaging of FRET poses several optimization challenges largely related to fluorophore brightness and stability.
Procedure:
1) Label the Target with any conventional fluorescent probe;
2) Label Interactor 1 with STIM antibody against Interactor 1. Measure interaction strength between Target and Interactor 1;
3) Cleave fluorescent label on STIM antibody;
4) Label Interactor 2 with STIM antibody against Interactor 2. Measure interaction strength between Target and Interactor 2;
5) Cleave fluorescent label on STIM antibody;
6) Label Interactor 3 with STIM antibody against Interactor 3. Measure interaction strength between Target and Interactor 3.
7) Repeat process.
Antibodies for STIM may be a conventional antibody raised in mouse/rabbit and anti mouse/rabbit Fab fragment labeled with dye via cleavable disulfide bond. The antibodies are then incubated for 1-3 hours at room temperature. Next, unbound F(ab) fragments are filtered out and the remaining antibodies for STIM are applied to the cell sample. STIM probes were found to be as robust as conventional antibody probes and they were cleavable by disulfide reducers. The sample was able to be re-probed.
The fluorescent probe developed (
After the sample is imaged, it can be destained (
Immunostains done using a biotinylated primary and an anti-biotin F(ab)-SS-GFP exhibit the same robust specificity as immunostains done using conventional primary and secondary antibodies. By way of example, using either staining approach, stains for a Catenin, Arp 3, and Myosin 2b in COS-7 cells (
The feature of the anti-biotin F(ab)-SS-XFP staining system most relevant to serial staining is the ability to destain the sample under mild conditions. Destaining is effected by cleaving the GFP off the sample using a disulfide reducing agent such as TCEP or DTT. The effectiveness of this cleaving depends on both time and concentration of the disulfide reducing agent. It was found that a 1 hour wash with 20-50 mM TCEP (in 100 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.3% Triton-X 100) is adequate to remove essentially all of the GFP signal. A similar quality of staining and destaining occurs with anti-biotin F(ab)-SS-mCherry (
An iterative serial stain involves repeatedly staining, imaging, and destaining the same region of a sample with multiple cleavable stains (
To illustrate this process (
An automated stage was used to return to approximately the same field of view in each imaging round. Fine offsets in the field of view from round to round can be compensated for by software using the permanent stain as a landmark map.
A critical feature of the probes we have developed is the use of a fluorescent protein (e.g. GFP) instead of a conventional small-molecule fluorophore (e.g. fluorescein, Cy5) to label the F(ab) fragments. Small-molecule fluorophores were found to become partially non-cleavable when exposed to excitation light during imaging. As an illustrative comparison, CF488A (a green fluorophore similar to fluorescein) and GFP are used to label anti-Rabbit F(ab) fragments, generating anti-Rabbit F(ab)-SS-CF488A and F(ab)-SS-GFP. These F(ab) fragments are then used to stain a Rabbit primary antibody against Myosin 2b in fixed COS-7 cells (
The excitation induced formation of a non-destainable fluorescence does not specifically require a disulfide bond nor even a direct covalent link between the excited fluorophore and the cleavable bond. We generated a destainable stain of Myosin 2b using an anti-Rabbit F(ab) fragment labeled with biotin via a cleavable diazo bond (
While the mechanism of the excitation induced formation of a non-cleavable bond is not understood, it was hypothesized that upon excitation with light, the fluorophore enters a reactive excited state that can form a non-cleavable covalent bond with nearby intracellular molecules (proteins, etc). While the disulfide bond is cleavable by TCEP, this new bond is not, and hence the fluorophore cannot be fully removed by TCEP. This phenomenon has been observed and even utilized for the light induced patterning of a protein coated surface with a fluorophore (Holden & Cremer, 2003; Jayagopal, Stone, & Haselton, 2008).
If the small-molecule fluorophore becomes non-cleavable because its excited state reacts with its surroundings to form a covalent bond, then it follows that preventing the excited state fluorophore from coming into contact with the intracellular environment will prevent the formation of such a non-cleavable bond. Fluorescent proteins such as GFP (mCherry, YFP, CFP, etc) consist of a small fluorescent group surrounded by a protein beta barrel. This beta barrel serves as an inert shell that prevents the fluorophore from coming into contact with its intracellular surroundings. Hence GFP should not form any non-cleavable bonds with its surroundings upon excitation with light. Indeed, we find that F(ab)-SS-GFP can be fully cleaved and removed from the sample (
This light induced formation of a non-cleavable bond in the case of small-molecule cleavable fluorophores has not been previously observed or reported in the literature, and therefore the solution to this problem is novel, inventive and non-obvious.
This technology can be used where multiplexing technologies are currently used with small molecule fluorophores, such as in screening for cancer cells, or where primary antibodies exist for the biological target of interest.
Primary antibodies were purchased against Myosin 2b (Sigma-Aldrich M7939), a Catenin (Assay Biotech C0137), Drebrin A/E (Millipore AB10140), Arp 3 (Abeam ab49671). Care was taken to select only antibodies that do not have other proteins (e.g. BSA) in the storage buffer. These antibodies were cleavably biotinylated using EZ-Link Sulfo-NHS-SS-Biotin (Thermo Fisher Scientific 21331).
Small volumes of these antibodies were cleavably biotinylated to test the optimal level of biotinylation. Too little biotinylation results in a weak fluorescence signal due to insufficient anti-biotin F(ab)-SS-GFP binding. Too much biotinylation can disrupt the primary antibody binding of its antigen, also leading to a low and non-specific fluorescence. 1 μl of 1 mg/ml primary antibody was mixed with 1 μl of 1 mM, 3 mM, and 10 mM EZ-Link Sulfo-NHS-SS-Biotin in PBS pH 7.4. The mixture was incubated at room temperature for 15 minutes. 10 ul of (100 mM Tris-HCl+150 mM NaCl, pH 7.4) was then added for 5 minutes to stop the reaction and quench any unconjugated Sulfo-NHS-SS-Biotin. The entire volume was then filtered through a 40 kD Zeba Micro Spin Desalting Column (Thermo Fisher Scientific 87764) to remove any unbound Biotin and exchange the buffer to PBS pH 7.4.
Each of these biotinylated primary antibodies were used to stain samples of fixed COS-7 cells with anti-biotin F(ab)-SS-GFP (see staining protocol). The samples were then imaged to determine which level of biotinylation gave the most fluorescence signal.
F(ab)-SS-XFP was synthesized by linking anti-biotin F(ab) to recombinant GFP (or mCherry) using the Solulink linker technology. 180 μM recombinant GFP (or 240 μM mCherry) was mixed with 2 mM S-HyNic (Solulink S-1002-010; from 20 mM stock in DMSO) for 3 hours at room temperature. Excess unreacted S-HyNic was removed by filtering the mixture through Micro Bio-Spin P-6 Gel Columns (Bio-Rad 7326221) twice. This generated 60 μM GFP-HN (or 90 μM mCherry-HN) as measured by absorbance.
Anti-biotin F(ab) (Rockland 800-101-098) was concentrated to 4 mg/ml using an Amicon Ultra 0.5 ml 10K centrifugal filter (Millipore UFC501024) and then mixed with 1 mM S-SS-4FB (Solulink S-1037-010; from 20 mM stock in DMF) for 3 hours at room temperature. Excess unreacted S-SS-4FB was removed by filtering the mixture through Micro Bio-Spin P-6 Gel Columns twice. This generated 30 μM anti-biotin F(ab)-SS-4FB as measured by absorbance.
Anti-biotin F(ab)-SS-GFP was then generated by mixing 5 μl anti-biotin F(ab)-SS-4FB+2 μl GFP-HN+2 ul PBS+1 ul 10× Turbolink Catalyst Buffer (Solulink 5-2006-105) for 30 minutes at room temperature. The mixture was then filtered through a 50 kD Amicon Ultra centrifugal filter (Milipore UFC505024) for 3 10-minute spins to remove any unconjugated F(ab) and GFP.
COS-7 cells were grown on glass substrates until they were ˜50% confluent. Cells were fixed in 4% PFA in PBS for 15 minutes at room temperature. The cells were then permeablized and blocked with Blockaid (Thermo Fisher Scientific B-10710)+0.3% Triton-X 100 for 1 hour at room temperature. Staining of the cleavably biotinylated primary was done overnight at 4° C. or for 3 hours at room temperature at 1/100- 1/300 dilution into Blockaid+0.3% Triton-X 100. After a thorough wash in PBS, the anti-biotin F(ab)-SS-GFP was also applied at 1/100- 1/300 dilution into Blockaid+0.3% Triton-X 100 overnight at 4° C. or for 3 hours at room temperature.
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., . . . Ginty, F. (2013). Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proceedings of the National Academy of Sciences of the United States of America, 110(29), 11982-11987. doi: 10.1073/pnas.1300136110.
Holden, M. A., & Cremer, P. S. (2003). Light activated patterning of dye-labeled molecules on surfaces. Journal of the American Chemical Society, 125(27), 8074-8075. doi: 10.1021/ja035390e.
Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682-690. doi: 10.1038/nchembio.118.
Jayagopal, A., Stone, G. P., & Haselton, F. R. (2008). Light-guided surface engineering for biomedical applications. Bioconjugate Chemistry, 19(3), 792-796. doi: 10.1021/bc700406w
Jungmann, R., Avendano, M. S., Woehrstein, J. B., Dai, M. J., Shih, W. M., & Yin, P. (2014). Multiplexed 3D cellular super-resolution imaging with DNA-PAINT and Exchange-PAINT. Nature Methods, 11(3), 313-U292. doi: 10.1038/nmeth.2835
Micheva, K. D., & Smith, S. J. (2007). Array tomography: A new tool for Imaging the molecular architecture and ultrastructure of neural circuits. Neuron, 55(1), 25-36. doi: 10.1016/j.neuron.2007.06.014.
Nelson, D. A., Manhardt, C., Kamath, V., Sui, Y. X., Santamaria-Pang, A., Can, A., . . . Larsen, M. (2013). Quantitative single cell analysis of cell population dynamics during submandibular salivary gland development and differentiation. Biology Open, 2(5), 439-447. doi: 10.1242/bio.20134309.
Schubert, W., Bonnekoh, B., Pommer, A. J., Philipsen, L., Bockelmann, R., Malykh, Y., . . . Dress, A. W. M. (2006). Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. Nature Biotechnology, 24(10), 1270-1278. doi: 10.1038/nbt1250.
Abul-Husn, N. S., I. Bushlin, J. A. Moron, S. L. Jenkins, G. Dolios, R. Wang, R. Iyengar, A. Ma'ayan, and L. A. Devi. 2009. Systems approach to explore components and interactions in the presynapse. Proteomics 9:3303-3315.
Li, K. W., M. P. Hornshaw, R. C. Van der Schors, R. Watson, S. Tate, B. Casetta, C. R. Jimenez, Y. Gouwenberg, E. D. Gundelfinger, K. H. Smalla, and A. B. Smit. 2004. Proteomics analysis of rat brain postsynaptic density—Implications of the diverse protein functional groups for the integration of synaptic physiology. J. Biol. Chem. 279:987-1002.
Choudhary, J., and S. G. N. Grant. 2004. Proteomics in postgenomic neuroscience: the end of the beginning. Nat. Neurosci. 7:440-445.
Yoshimura, Y., Y. Yamauchi, T. Shinkawa, M. Taoka, H. Donai, N. Takahashi, T. Isobe, and T. Yamauchi. 2004. Molecular constituents of the postsynaptic density fraction revealed by proteomic analysis using multidimensional liquid chromatography-tandem mass spectrometry. J. Neurochem. 88:759-768.
Collins, M. O., H. Husi, L. Yu, J. M. Brandon, C. N. G. Anderson, W. P. Blackstock, J. S. Choudhary, and S. G. N. Grant. 2006. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97:16-23.
Husi, H., M. A. Ward, J. S. Choudhary, W. P. Blackstock, and S. G. N. Grant. 2000. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3:661-669.
Pocklington, A. J., M. Cumiskey, J. D. Armstrong, and S. G. N. Grant. 2006. The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. Mol. Syst. Biol. 2.
De Las Rivas, J., and C. Fontanillo. 2010. Protein-Protein Interactions Essentials: Key Concepts to Building and Analyzing Interactome Networks. Plos Computational Biology 6.
Hopkins, A. L. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-690.
Fredriksson, S., M. Gullberg, J. Jarvius, C. Olsson, K. Pietras, S. M. Gustafsdottir, A. Ostman, and U. Landegren. 2002. Protein detection using proximity-dependent DNA ligation assays. Nat. Biotechnol. 20:473-477.
Grant, D. M., W. Zhang, E. J. McGhee, T. D. Bunney, C. B. Talbot, S. Kumar, I. Munro, C. Dunsby, M. A. A. Neil, M. Katan, and P. M. W. French. 2008. Multiplexed FRET to Image Multiple Signaling Events in Live Cells. Biophys. J. 95:L69-L71.
Ramachandran, B., and J. U. Frey. 2009. Interfering with the Actin Network and Its Effect on Long-Term Potentiation and Synaptic Tagging in Hippocampal CA1 Neurons in Slices In Vitro. J. Neurosci. 29:12167-12173.
Fischer, M., S. Kaech, D. Knutti, and A. Matus. 1998. Rapid actin-based plasticity in dendritic spines. Neuron 20:847-854.
Fischer, M., S. Kaech, U. Wagner, H. Brinkhaus, and A. Matus. 2000. Glutamate receptors regulate actin-based plasticity in dendritic spines. Nat. Neurosci. 3:887-894.
Kim, C. H., and J. E. Lisman. 1999. A role of actin filament in synaptic transmission and long-term potentiation. J. Neurosci. 19:4314-4324.
Okamoto, K. I., T. Nagai, A. Miyawaki, and Y. Hayashi. 2004. Rapid and persistent modulation of actin dynamics regulates postsynaptic reorganization underlying bidirectional plasticity. Nat. Neurosci. 7:1104-1112.
Fukazawa, Y., Y. Saitoh, F. Ozawa, Y. Ohta, K. Mizuno, and K. Inokuchi. 2003. Hippocampal LTP is accompanied by enhanced F-actin content within the dendritic spine that is essential for late LTP maintenance in vivo. Neuron 38:447-460.
Micheva, K. D., B. Busse, N. C. Weiler, N. O'Rourke, and S. J. Smith. 2010. Single-Synapse Analysis of a Diverse Synapse Population: Proteomic Imaging Methods and Markers. Neuron 68:639-653.
Wahlby, C., F. Erlandsson, E. Bengtsson, and A. Zetterberg. 2002. Sequential immunofluorescence staining and image analysis for detection of large numbers of antigens in individual cell nuclei. Cytometry 47:32-41.
Gerdes, M. J., C. J. Sevinsky, A. Sood, S. Adak, M. O. Bello, A. Bordwell, A. Can, A. Corwin, S. Dinn, R. J. Filkins, D. Hollman, V. Kamath, S. Kaanumalle, K. Kenny, M. Larsen, M. Lazare, Q. Li, C. Lowes, C. C. McCulloch, E. McDonough, M. C. Montalto, Z. Y. Pang, J. Rittscher, A. Santamaria-Pang, B. D. Sarachan, M. L. Seel, A. Seppo, K. Shaikh, Y. X. Sui, J. Y. Zhang, and F. Ginty. 2013. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc. Natl. Acad. Sci. U. S. A. 110:11982-11987.
Brown, J. K., A. D. Pemberton, S. H. Wright, and H. R. P. Miller. 2004. Primary antibody-Fab fragment complexes: A flexible alternative to traditional direct and indirect Immunolabeling techniques. J. Histochem. Cytochem. 52:1219-1230.
Liu, H. C., and K. May. 2012. Disulfide bond structures of IgG molecules Structural variations, chemical modifications and possible impacts to stability and biological function. mAbs 4:17-23.
Lin, Y. C., and A. J. Koleske. 2010. Mechanisms of Synapse and Dendrite Maintenance and Their Disruption in Psychiatric and Neurodegenerative Disorders. In Annual Review of Neuroscience, Vol 33. S. E. Hyman, editor. Annual Reviews, Palo Alto. 349-378.
Sun, Y. S., R. N. Day, and A. Periasamy. 2011. Investigating protein-protein interactions in living cells using fluorescence lifetime imaging microscopy. Nat. Protoc. 6:1324-1340.
Lakowicz, J. R. 1999. Principles of Fluorescence Spectroscopy. Springer, New York.
Hermanson, G. T. 2013. Bioconjugate Techniques. Academic Press.
Nakagawa, Y., Capetill. S, and Jirgenso. B. 1972. Effect of chemical modification of lysine residues on confomation of human immunoglobulin-G. J. Biol. Chem. 247:5703-&.
Berlier, J. E., A. Rothe, G. Buller, J. Bradford, D. R. Gray, B. J. Filanoski, W. G. Telford, S. Yue, J. X. Liu, C. Y. Cheung, W. Chang, J. D. Hirsch, J. M. Beechem, and R. P. Haugland. 2003. Quantitative comparison of long-wavelength Alexa Fluor dyes to Cy dyes: Fluorescence of the dyes and their bioconjugates. J. Histochem. Cytochem. 51:1699-1712.
Wu, P. G., and L. Brand. 1994. Resonance energy transfer—methods and applications. Anal. Biochem. 218:1-13.
Podgorski, K., E. Terpetschnig, O. P. Klochko, O. M. Obukhova, and K. Haas. 2012. Ultra-Bright and -Stable Red and Near-Infrared Squaraine Fluorophores for In Vivo Two-Photon Imaging. PLoS One 7.
Longin, A., C. Souchier, M. Ffrench, and P. A. Bryon. 1993. Comparison of anti-fading agenst used in fluorescence microscopy—image-analysis and laser confocal microscopy study. J. Histochem. Cytochem. 41:1833-1840.
Yun, C. S., A. Javier, T. Jennings, M. Fisher, S. Hira, S. Peterson, B. Hopkins, N. O. Reich, and G. F. Strouse. 2005. Nanometal surface energy transfer in optical rulers, breaking the FRET barrier. J. Am. Chem. Soc. 127:3115-3119.
Cingolani, L. A., and Y. Goda. 2008. Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat. Rev. Neurosci. 9:344-356.
Hotulainen, P., and C. C. Hoogenraad. 2010. Actin in dendritic spines: connecting dynamics to function. J. Cell Biol. 189:619-629.
This application claims the benefit of U.S. Provisional Application No. 62/313,027, filed Mar. 24, 2016, the entire contents of which are hereby incorporated by reference herein.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US17/23985 | 3/24/2017 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62313027 | Mar 2016 | US |